• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (GRADUAL-1) of Bofanglutide (GZR18) injection in Chinese Patients with Overweight or Obesity
    Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (GRADUAL-1) of Bofanglutide (GZR18) injection in Chinese Patients with Overweight or Obesity
    Date:2024-12-30

    Beijing, China, December 30, 2024 – Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) announced that the first participant has been successfully dosed in a Phase 3 clinical trial (GRADUAL-1) of Bofanglutide (research code: GZR18), a glucagon-like peptide-1 receptor agonist (GLP-1RA) bi-weekly formulation independently developed Gan & Lee, in Chinese partcipants with overweight or obesity. This marks the formal initiation of the first GLP-1 RA biweekly formulation for the indication of overweight or obesity into Phase 3 clinical development globally.

     

    This Phase 3 clinical trial was designed to evaluate the efficacy and safety of Bofanglutide injection in Chinese adults with overweight or obesity whose weight was inadequately controlled by diet and exercise (ClinicalTrials.gov registration number: NCT06728124). The study plans to enroll 630 subjects who will be randomly assigned to receive treatment of either 24 mg of Bofanglutide bi-weekly, 48 mg of Bofanglutide bi-weekly, or placebo. The primary endpoints include the percentage change in body weight from baseline and the proportion of subjects with 5% or more body weight loss from baseline.

     

    Previously, a Phase 2 study (NCT06256562) of Bofanglutide injection in Chinese subjects with overweight or obesity showed that after 30 weeks of treatment, the mean percentage in boday weight reduction from baseline was ?14.3% in the bi-weekly 24 mg group and ?17.3% in the bi-weekly 48 mg group. Additionally, Bofanglutide significantly reduced waist circumference and BMI, improved cardiovascular and glucose metabolism indicators, and demonstrated good safety and tolerability, with a safety profile similar to other GLP-1 receptor agonists.

     

    Professor Linong Ji from Peking University People's Hospital, the leading principal investigator of the GRADUAL-1 study, stated, "Obesity has become a critical global public health issue and is rapidly spreading in China. According to Chinese standards, nearly half of the population is currently in the obesity (BMI ≥28 kg/m2) or overweight (24 kg/m2 ≤ BMI <28 kg/m2) condition. By 2030, this proportion is expected to rise to 63%1. Obesity is not only a significant risk factor for diabetes and cardiovascular diseases but also places a substantial economic burden on society. Currently, many weight-loss medications require frequent injections, causing inconvenience to patients who generally prefer oral medications or therapies with lower dosing frequencies. Bofanglutide, as a bi-weekly GLP-1 RA, demonstrated remarkable weight-loss efficacy in Phase 2 clinical trials, along with improvements in fasting blood glucose, blood pressure, lipids, and other metabolic indicators, as well as overall safety and tolerability. I look forward to further confirming the efficacy and safety of Bofanglutide in Phase 3 trials to provide robust evidence for its market approval."


    About Gan & Lee

    Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

     

    In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 久久精品久久久久观看99水蜜桃| 亚洲综合激情六月婷婷在线观看 | 把极品白丝班长啪到腿软| 国产50部艳色禁片无码| 一个人看日本www| 高清性色生活片a| 日本pissjapantv厕所自| 午夜影视在线免费观看| 99re热这里只有精品| 极品美女aⅴ高清在线观看| 国产亚洲Av综合人人澡精品| 一级白嫩美女毛片免费| 污视频网站免费在线观看| 国产精品videossex国产高清| 久久午夜综合久久| 竹菊影视国产精品 | 国产精品大片天天看片| 新梅瓶4在线观看dvd| 人人爽人人爽人人片a免费| bbw巨大丰满xxxx| 欧美亚洲国产片在线观看| 国产又黄又爽又刺激的免费网址| 久久精品中文闷骚内射| 精品天海翼一区二区| 国产精品自在线拍国产手机版 | 亚洲国产视频网| 野花社区视频www| 女人国产香蕉久久精品| 亚洲一级在线观看| 国产主播在线播放| 成人动漫视频在线| 亚洲国产高清人在线| 色多多网站入口| 国农村精品国产自线拍| 久久亚洲私人国产精品va| 男人天堂999| 国产性生大片免费观看性| www..99557c..com| 日韩精品一区二区三区中文精品| 内射白嫩少妇超碰| jizz18高清视频|